What Google Ventures does

GV (Google Ventures) is the venture capital arm of Alphabet, founded in 2009 as Google Ventures and rebranded to GV in 2015. The firm operates as an independent multi-stage investor with Alphabet as its sole limited partner, managing over $13 billion in assets under management and supporting approximately 400 active portfolio companies across North America, Europe, and Israel. GV invests from seed to growth stages in technology and life sciences, organized around dedicated sector focus areas — AI Applications (50+ companies including Harvey, Hebbia, Synthesia), Healthcare and Life Sciences (20 AI healthcare companies including insitro and Isomorphic Labs), Dev Tools and Security (Vercel, StackBlitz/Bolt.new), and AI Infrastructure (Snorkel, SambaNova, Modular, Lightmatter). The firm has a track record of 80+ portfolio IPOs and 230+ M&A outcomes, with marquee realizations including Uber, Stripe, Slack, GitLab, Flatiron Health, Lemonade, and One Medical.

GV's investment platform combines traditional multi-stage capital (operating on decade-long horizons) with operating-partner support services spanning executive talent, communications, and marketing, plus structured access to Google and Alphabet companies for portfolio founders. The firm is led by CEO and Managing Partner David Krane alongside Managing Partners Dave Munichiello, Krishna Yeshwant, and Tom Hulme (head of Europe), supported by a deep bench of 13+ General Partners covering AI/enterprise, consumer, frontier tech, and life sciences, and Executive Venture Partners drawn from senior industry roles (Cathy Friedman, ex-Morgan Stanley; Dan Lynch, ex-ImClone CEO). Revenue is generated through standard venture capital fund economics — management fees on committed capital plus carried interest on portfolio exits — with fund structure insulated from competitive fundraising pressure by Alphabet's sole-LP commitment.

Geographically, GV is headquartered in the San Francisco Bay Area with regional hubs in New York (opened 2010), Cambridge (life sciences), and London (European headquarters, opened 2014), and recently extended into Continental Europe with its first French investment (MokN, May 2026). The firm's value proposition centers on the combination of single-LP reliability, traditional-VC autonomy (including the ability to invest in direct competitors of Alphabet), and founder-grade technical expertise drawn from computer scientists, engineers, genomicists, and prior operators. In 2026 the firm has visibly leaned into AI-native investing, co-leading mega-rounds in AI customer experience (Sierra, $950M Series E at $15B+ valuation), self-improving AI systems (Recursive Superintelligence, $650M at $4.65B), neuro-AI (Flourish, $500M at $2.5B), and AI drug discovery (Isomorphic Labs, $2.1B Series B participation).

Name

Google Ventures

Legal name

GV

Website

https://gv.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

GV (Google Ventures) is Alphabet's multi-stage venture capital arm, investing from seed to growth across technology and life sciences with $13B+ AUM, 400 active portfolio companies, and 80+ IPOs and 230+ M&A outcomes to date. The firm is AI-thesis-heavy, with 100+ AI companies backed across infrastructure, applications, and healthcare.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Technology & Software Growth Equity (FSANACAA)

akta.pro secondary industries

Multi-Sector / Generalist Growth Equity (FSANACAO), Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Venture capital investing
• Technology venture funding
• Seed stage capital
• Growth stage equity
• Life sciences investing

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Venture Capital Fund Management: GV generates revenue through standard venture capital fund economics: management fees on assets under management ($13B+) and carried interest (profit participation) on successful portfolio exits including 80+ IPOs and 230+ M&A transactions. Alphabet is the sole limited partner.
2. Investment Returns: Returns generated from equity stakes in 400 active portfolio companies across seed, early-stage, and growth stages. Notable outcomes include Uber, Slack, Nest, GitLab, Flatiron Health, Lemonade, and others.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

GV (Google Ventures) is Alphabet's venture capital arm, deploying multi-stage venture capital funds from seed to growth across technology and life sciences sectors. The firm invests equity capital in early-stage and growth-stage companies while providing operating partner support across executive talent, communications, and marketing, leveraging unique access to Google's people, products, and global reputation.

Product overview

GV (Google Ventures) is Alphabet's venture capital arm, operating as a multi-stage investment platform (single unified investment firm with sector-specific focus areas) rather than a platform-plus-modules product. Founded in 2009 and rebranded from Google Ventures to GV in 2015, GV manages over $13 billion in assets and supports 400 active portfolio companies across North America, Europe, and Israel. Its investment activity is organized around dedicated sector focus areas — AI Applications (e.g., Harvey, Hebbia, Synthesia, OpenEvidence, Thinking Machines Lab), Healthcare/Life Sciences (e.g., insitro, Isomorphic Labs), Dev Tools & Security (e.g., Stackblitz/Bolt.new, Vercel), and Infrastructure (e.g., Snorkel, Deepset, SambaNova, Modular, Lightmatter) — supplemented by Consumer, Enterprise, and Frontier Tech coverage. Across all these sectors, GV's "Multi-Stage Venture Capital Funds (Seed to Growth)" deliver the underlying capital product, while its "Portfolio Operating Partner Support" wraps executive-talent, communications, and marketing services around founders, and its "Cross-Border Investment Program (North America, Europe, Israel)" extends the geographic reach from its San Francisco Bay Area headquarters and offices in New York, Cambridge, and London.

Differentiator

Problem solved

Functional benefit

Products and services

• Multi-Stage Venture Capital Funds (Seed to Growth) Equity capital investments provided to technology and life sciences companies across all stages from seed to growth, operating on long time horizons measured in decades. Capital is deployed across sector focus areas including AI Applications, Healthcare/Life Sciences, Dev Tools & Security, Infrastructure, Consumer, Enterprise, and Frontier Tech.
• Portfolio Operating Partner Support Non-capital support services provided to portfolio company founders across executive talent, communications, marketing, and introductions to Google and Alphabet companies. Helps founders with the venture-building journey beyond financial capital alone.
• Cross-Border Investment Program (North America, Europe, Israel) Multi-region venture capital investment program covering North America, Europe, and Israel with offices in San Francisco Bay Area (headquarters), New York, Cambridge (MA), and London. Enables investment in founders across three continents under a unified fund mandate.

Quantifiable outcome

• $13 billion in assets under management (up from $60M initial commitment)
• +4 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

16 partnerships are on record, tiered flagship and core.

• Parabilis Medicines (formerly FOG Pharma)flagshipStrategic or Co-development PartnerLong-term portfolio partnership dating from 2018 Series B financing. Parabilis went public in June 2026, validating GV's early bet on stapled peptides targeting 'undruggable' beta-catenin in desmoid tumors and familial adenomatous polyposis. The company's lead therapeutic candidate zolucatetide is in clinical trials.
• Recursive SuperintelligenceflagshipStrategic or Co-development PartnerGV co-led Recursive Superintelligence's $650M early funding at a $4.65 billion valuation. Recursive is building self-improving AI systems led by Richard Socher with seven co-founders from DeepMind, OpenAI, Salesforce, and UCL.
• SierraflagshipStrategic or Co-development PartnerGV co-led Sierra's Series E financing in May 2026 at $15B+ valuation. Sierra is an AI customer experience platform co-founded by Bret Taylor and Clay Bavor serving 40% of Fortune 50.
• MokNcoreStrategic or Co-development PartnerGV led MokN's Series A in May 2026 ($15M), marking GV's first investment in a French startup. MokN is pioneering Active Identity Recovery with its 'Phish-Back' solution. Luna Schmid joined the board.
• OpenEvidencecoreStrategic or Co-development PartnerGV portfolio company in AI for doctors; invested in 2025. Sangeen Zeb is the GV lead on the board. Used by approximately 65% of US doctors.
• LightmattercoreStrategic or Co-development PartnerPortfolio company in AI infrastructure focusing on photonic computing; one of GV's early AI infrastructure investments.
• SambaNova SystemscoreStrategic or Co-development PartnerPortfolio company in AI infrastructure; one of GV's early AI infrastructure investments.
• Snorkel AIcoreStrategic or Co-development PartnerPortfolio company in data labeling and AI infrastructure; raised $100M Series D in May 2025 at $1.3B valuation.
• ModularcoreStrategic or Co-development PartnerPortfolio company building GPU software infrastructure led by former Apple luminary Chris Lattner.
• HarveycoreStrategic or Co-development PartnerPortfolio company providing AI for legal workflows; Sangeen Zeb sits on the board. Reached $11B valuation.
• Thinking Machines LabcoreStrategic or Co-development PartnerPortfolio company in foundation models and AI infrastructure. Sangeen Zeb is the GV lead.
• VercelcoreStrategic or Co-development PartnerPortfolio company in developer tools/frontend cloud platform; Sangeen Zeb sits on the board.
• Devoted HealthcoreStrategic or Co-development PartnerPortfolio company in healthcare delivery serving 466,000+ members across 29 states; raised $366M in 2026 (Series F $48M + Series F-Prime $317M).
• InsitrocoreStrategic or Co-development PartnerPortfolio company in AI-driven drug discovery, featured prominently on GV's AI Healthcare portfolio page.
• SynthesiacoreStrategic or Co-development PartnerPortfolio company in generative video AI; one of GV's featured AI applications investments.
• HebbiacoreStrategic or Co-development PartnerPortfolio company in AI for professional workflows; one of GV's featured AI application investments.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Andreessen Horowitz (a16z): Largest direct competitor to GV: multi-stage venture firm with technology and life-sciences focus, similar AUM scale, and a comparable founder-services platform — directly competes for the same AI, consumer, and enterprise deals.
• Sequoia Capital: Premier multi-stage technology and life-sciences investor operating in seed, venture, and growth stages; co-invests with and competes against GV across the same AI/healthcare/enterprise portfolio universe.
• General Catalyst: Multi-stage technology and healthcare investor; directly competes for the same AI application and healthcare deals (e.g., recently co-led a $1.2B round alongside GV).
• Accel: Long-standing technology-focused multi-stage venture firm with seed through growth capabilities; directly competes with GV on enterprise and consumer AI investments.
• Lightspeed Venture Partners: Multi-stage technology investor with strong AI, consumer, and enterprise focus; directly competes with GV on mid- and late-stage AI and SaaS rounds.
• Bessemer Venture Partners: Multi-stage venture firm with technology and healthcare focus; competes directly with GV on cloud, AI, and biotech growth rounds.
• Kleiner Perkins: Heritage multi-stage technology and life-sciences investor; historically one of the closest comparables to GV in stage, sector, and founder-service approach.
• Founders Fund: Technology-focused multi-stage venture firm; overlaps with GV on frontier AI, deep tech, and consumer investments.
• New Enterprise Associates (NEA): One of the largest multi-stage venture firms with broad sector coverage including technology and healthcare; comparable scale and stage breadth to GV.

Broad incumbents

• Insight Partners: Large-scale growth and late-stage technology investor; broader portfolio and larger AUM than GV but operates in adjacent stage/sector space, competing for the same growth-stage rounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/gvteam
• YouTubeyoutube.com/gv
• Facebookfacebook.com/GoogleVentures
• LinkedInlinkedin.com/company/googleventures
• Instagraminstagram.com/googleventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1420 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Google Ventures